Daniel J. Dammrich, MD – Achievements

Dr. Dan Dammrich MD
Achievements

Focus Area : Benign and Malignant Hematology, GI malignancy (stomach, colon, rectal, liver, pancreas, etc.)

Board Certifications

  • Internal Medicine
  • Hematology and Oncology

Residency / Fellowship

  • Fellowship, Hematology / Oncology – University of Miami Miller School of Medicine / Jackson Memorial Hospital – Miami, FL (2012-2015)
  • Residency, Internal Medicine – University of Miami Miller School of Medicine / Jackson Memorial Hospital – Miami, FL (2009-2012)

Higher Education

  • Loyola University Chicago Stritch School of Medicine, M.D. – Maywood, IL (2005-2009)
  • Loyola University, Post Baccalaureate/Pre-medical Program – Chicago, IL (2002-2004)
  • Boston College, B.A. – Chestnutt Hill, MA (1998-2002)

Award

  • Chief Hematology-Oncology Fellow; Hematology-Oncology Program. The University of Miami Miller School of Medicine / Jackson Memorial Hospital (2014-2015)

Research / Publications / Presentations

  • Dammrich D, Raez L, Santos E. Efficacy of Sorafenib, a multi-tyrosine kinase inhibitor, in an adenoid cystic carcinoma metastatic to the lung: case report and review of the literature. J Med Case Rep. 2011, Sep 27; 5:483 [PMID: 21951623].
  • Moh’d M. Khushman, Peter Joel Hosein, Michel Velez, Lauren Carcas, Daniel Joseph Dammrich, Jorge Hurtado-Cordovi, Ritesh Parajuli, Terri Pollack, Jessica MacIntyre, Ana Paula P. Harwood, Arturo Loaiza-Bonilla, Ikechukwu Immanuel Akunyili, Maria H. Restrepo, Jaime R. Merchan, Govindarajan Narayanan, Lorraine Portelance, Danny Sleeman, Joe U Levi, Caio Max S. Rocha Lima; Updated survival analysis of patients (pts) with unresectable (UR) or borderline resectable (BR) locally advanced pancreatic adenocarcinoma (LAPC) treated with neoadjuvant FOLFIRINOX. J Clin Oncol 32, 2014 (suppl; abstr e15197).
  • Yehuda E. Deutsch, MD; Daniel J Dammrich, MD; Jesus C Fabregas, MD; Agustin Pimentel, MD; Alexandra Stefanovic, MD; and James E. Hoffman, MD. Clinical experience of Lenalidomide plus low dose Dexamethasone as first-line therapy for multiple myeloma at a large county hospital caring for an indigent population. Blood, Nov 15, 2013; 122(21).
  • Alexandra Stefanovic, MD; Daniel Dammrich, MD; Andreas Tzakis, MD; Izidore Lossos, MD. Post-transplant lymphoproliferative disease in liver transplant recipients: a single institution experience. Blood, Nov 19, 2010.
  • Moh’d M. Khushman, Peter Joel Hosein, Michel Velez, Lauren Carcas, Daniel Joseph Dammrich, Jorge Hurtado-Cordovi, Ritesh Parajuli, Terri Pollack, Jessica Macintyre, Ana Paula P. Harwood, Arturo Loaiza-Bonilla, Ikechukwu Immanuel Akunyili, Maria H. Restrepo, Jaime R. Merchan, Govindarajan Narayanan, Lorraine Portelance, Danny Sleeman, Joe U Levi, Caio Max S. Rocha Lima; Efficacy and toxicities outcomes of patients (pt) with locally advanced pancreatic adenocarcinoma (LAPC) treated with neoadjuvant FOLFIRINOX (Accepted for poster presentation at 2014 ESMO).
  • Laren Peirce Carcas, Jessica MacIntyre, Monica Garcia-Buitrago, Jaime Merchan, Peter Hosein, Maria Restrepo, Ikechukwu Akunyili, Isildinha Reis, Joe Levi, Danny Sleeman, Moh’d Khushman, Daniel Dammrich, Yehuda Deutsch. The value of tissue phenotype as a predictor in advanced pancreatic ductal adenocarcinoma (PDAC) receiving either Gemcitabine (G) or FOLFIRINOX (F). (Poster AACR: Special Conference on Pancreatic Cancer 2014).
  • Stefanovic A, Dammrich D, Tzakis A, Losso I. Post-transplant lymphoproliferative disease in liver transplant recipients: A single institution experience. 2010 Annual Meeting of the American Society of Hematology. Dec 2010.
  • Sudhindra A, Dammrich D, Ochoa R, Takita C, Mendiola MF, Hurley J, Gluck S, Welsh C, Slingerland J, Richman S, Gomez-Fernandez C, Timothee P, Diaz A, Silva OE. Body Mass Index (BMI) and Survival: A Retrospective Review of Women with Triple Negative Breast Cancer (An Update). Thirty-Third Annual CTRC-AACR San Antonio Breast Cancer Symposium, Dec 8-12, 2010.

Comments are closed.